- In December 2023, Glaukos Corporation received FDA approval for its iDose TR, a travoprost intraocular implant developed to provide long-term reduction of intraocular pressure (IOP) in glaucoma patients. Designed for sustained drug delivery, iDose TR offers an alternative to daily eye drops, with efficacy lasting up to 36 months. This milestone reflects the growing adoption of minimally invasive, long-duration glaucoma therapies
- In September 2022, Glaukos Corporation announced a significant milestone of more than one million iStent family of technologies implanted worldwide. This achievement solidified Glaukos's position as the corporate founder and pioneer of the micro-invasive glaucoma surgery (MIGS) marketplace, reflecting decades of investment in innovative therapies for glaucoma patients
- In November 2021, iSTAR Medical received European market approval for its MINIject implant, marking a pivotal milestone in the glaucoma treatment landscape. MINIject became the only commercially available minimally invasive glaucoma surgery (MIGS) device targeting the supraciliary space, providing a new treatment pathway for open-angle glaucoma
